5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A nutritional biomarker score of the Mediterranean diet and incident type 2 diabetes: Integrated analysis of data from the MedLey randomised controlled trial and the EPIC-InterAct case-cohort study

      research-article
      1 , 1 , 2 ,   1 , 1 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 1 , 12 , 13 , 14 , 15 , 7 , 16 , 17 , 18 , 19 , 20 , 21 , 9 , 10 , 22 , 22 , 7 , 23 , 24 , 25 , 20 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 27 , 33 , 34 , 35 , 36 , 37 , 38 , 34 , 35 , 39 , 2 , 1 , 1 , * ,
      PLOS Medicine
      Public Library of Science

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Self-reported adherence to the Mediterranean diet has been modestly inversely associated with incidence of type 2 diabetes (T2D) in cohort studies. There is uncertainty about the validity and magnitude of this association due to subjective reporting of diet. The association has not been evaluated using an objectively measured biomarker of the Mediterranean diet.

          Methods and findings

          We derived a biomarker score based on 5 circulating carotenoids and 24 fatty acids that discriminated between the Mediterranean or habitual diet arms of a parallel design, 6-month partial-feeding randomised controlled trial (RCT) conducted between 2013 and 2014, the MedLey trial (128 participants out of 166 randomised). We applied this biomarker score in an observational study, the European Prospective Investigation into Cancer and Nutrition (EPIC)-InterAct case-cohort study, to assess the association of the score with T2D incidence over an average of 9.7 years of follow-up since the baseline (1991 to 1998). We included 22,202 participants, of whom 9,453 were T2D cases, with relevant biomarkers from an original case-cohort of 27,779 participants sampled from a cohort of 340,234 people. As a secondary measure of the Mediterranean diet, we used a score estimated from dietary-self report. Within the trial, the biomarker score discriminated well between the 2 arms; the cross-validated C-statistic was 0.88 (95% confidence interval (CI) 0.82 to 0.94). The score was inversely associated with incident T2D in EPIC-InterAct: the hazard ratio (HR) per standard deviation of the score was 0.71 (95% CI: 0.65 to 0.77) following adjustment for sociodemographic, lifestyle and medical factors, and adiposity. In comparison, the HR per standard deviation of the self-reported Mediterranean diet was 0.90 (95% CI: 0.86 to 0.95). Assuming the score was causally associated with T2D, higher adherence to the Mediterranean diet in Western European adults by 10 percentiles of the score was estimated to reduce the incidence of T2D by 11% (95% CI: 7% to 14%). The study limitations included potential measurement error in nutritional biomarkers, unclear specificity of the biomarker score to the Mediterranean diet, and possible residual confounding.

          Conclusions

          These findings suggest that objectively assessed adherence to the Mediterranean diet is associated with lower risk of T2D and that even modestly higher adherence may have the potential to reduce the population burden of T2D meaningfully.

          Trial registration

          Australian New Zealand Clinical Trials Registry (ANZCTR) ACTRN12613000602729 https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=363860.

          Abstract

          Jakub G Sobiecki and team aim to develop a biomarker score able to discriminate between Mediterranean diet and habitual diet, and test its association with incident type 2 diabetes in a European cohort.

          Author summary

          Why was this study done?
          • Epidemiological evidence has indicated that greater self-reported adherence to the Mediterranean diet may be associated with lower risk of new onset type 2 diabetes (T2D), but there has been uncertainty about the magnitude of association due to subjective reporting of diet.

          • A combination of nutritional biomarkers could better assess diet–disease associations, but this approach has rarely been considered for overall diet quality, particularly for the association between the Mediterranean diet and T2D.

          What did the researchers do and find?
          • Blood carotenoids and fatty acids can be used as an objective measure of adherence to the Mediterranean diet, as indicated by results from a trial ( n = 128) of adopting Mediterranean diet with provision of its key foods to study participants. These biomarkers discriminated well between the trial participants under the Mediterranean diet intervention and those randomised to continuation of habitual diet (C-statistic = 0.88).

          • In a study across 8 European countries ( n = 22,202), adherence to the Mediterranean diet, estimated using a combination of nutritional biomarkers, was associated with lower risk of new onset T2D, with a stronger relationship compared to that with self-reported Mediterranean diet. The hazard ratios (HRs) (95% confidence interval (CI)) per standard deviation of adherence were 0.71 (0.65 to 0.77) and 0.90 (0.86 to 0.95), respectively.

          What do these findings mean?
          • Adherence to the Mediterranean diet may be more beneficial for the primary prevention of T2D than previously estimated from observational dietary studies.

          • Even small upward differences in objectively measured Mediterranean diet may be associated with a sizeable reduction of the risk of T2D at the population level.

          • Causal interpretation of these findings is limited by potential measurement error in nutritional biomarkers, unclear specificity of the biomarker score to the Mediterranean diet, and possible residual confounding.

          Related collections

          Most cited references78

          • Record: found
          • Abstract: found
          • Article: not found

          The meaning and use of the area under a receiver operating characteristic (ROC) curve.

          A representation and interpretation of the area under a receiver operating characteristic (ROC) curve obtained by the "rating" method, or by mathematical predictions based on patient characteristics, is presented. It is shown that in such a setting the area represents the probability that a randomly chosen diseased subject is (correctly) rated or ranked with greater suspicion than a randomly chosen non-diseased subject. Moreover, this probability of a correct ranking is the same quantity that is estimated by the already well-studied nonparametric Wilcoxon statistic. These two relationships are exploited to (a) provide rapid closed-form expressions for the approximate magnitude of the sampling variability, i.e., standard error that one uses to accompany the area under a smoothed ROC curve, (b) guide in determining the size of the sample required to provide a sufficiently reliable estimate of this area, and (c) determine how large sample sizes should be to ensure that one can statistically detect differences in the accuracy of diagnostic techniques.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Regularization and variable selection via the elastic net

              Bookmark
              • Record: found
              • Abstract: found
              • Article: found

              Multiple imputation using chained equations: Issues and guidance for practice

              Multiple imputation by chained equations is a flexible and practical approach to handling missing data. We describe the principles of the method and show how to impute categorical and quantitative variables, including skewed variables. We give guidance on how to specify the imputation model and how many imputations are needed. We describe the practical analysis of multiply imputed data, including model building and model checking. We stress the limitations of the method and discuss the possible pitfalls. We illustrate the ideas using a data set in mental health, giving Stata code fragments. 2010 John Wiley & Sons, Ltd.
                Bookmark

                Author and article information

                Contributors
                Role: ConceptualizationRole: Formal analysisRole: InvestigationRole: MethodologyRole: Project administrationRole: VisualizationRole: Writing – original draftRole: Writing – review & editing
                Role: ConceptualizationRole: InvestigationRole: MethodologyRole: SupervisionRole: Writing – review & editing
                Role: InvestigationRole: MethodologyRole: Writing – review & editing
                Role: InvestigationRole: MethodologyRole: SupervisionRole: Writing – review & editing
                Role: Data curationRole: InvestigationRole: MethodologyRole: ResourcesRole: Writing – review & editing
                Role: InvestigationRole: MethodologyRole: Writing – review & editing
                Role: InvestigationRole: MethodologyRole: Writing – review & editing
                Role: InvestigationRole: MethodologyRole: Writing – review & editing
                Role: InvestigationRole: MethodologyRole: Writing – review & editing
                Role: InvestigationRole: ResourcesRole: Writing – review & editing
                Role: InvestigationRole: ResourcesRole: Writing – review & editing
                Role: InvestigationRole: ResourcesRole: Writing – review & editing
                Role: InvestigationRole: ResourcesRole: Writing – review & editing
                Role: InvestigationRole: ResourcesRole: Writing – review & editing
                Role: Data curationRole: InvestigationRole: ResourcesRole: Writing – review & editing
                Role: InvestigationRole: ResourcesRole: Writing – review & editing
                Role: InvestigationRole: ResourcesRole: Writing – review & editing
                Role: InvestigationRole: ResourcesRole: Writing – review & editing
                Role: InvestigationRole: ResourcesRole: Writing – review & editing
                Role: InvestigationRole: ResourcesRole: Writing – review & editing
                Role: InvestigationRole: ResourcesRole: Writing – review & editing
                Role: ConceptualizationRole: InvestigationRole: ResourcesRole: Writing – review & editing
                Role: InvestigationRole: ResourcesRole: Writing – review & editing
                Role: InvestigationRole: ResourcesRole: Writing – review & editing
                Role: InvestigationRole: ResourcesRole: Writing – review & editing
                Role: InvestigationRole: ResourcesRole: Writing – review & editing
                Role: InvestigationRole: ResourcesRole: Writing – review & editing
                Role: InvestigationRole: ResourcesRole: Writing – review & editing
                Role: Funding acquisitionRole: InvestigationRole: ResourcesRole: Writing – review & editing
                Role: Funding acquisitionRole: InvestigationRole: ResourcesRole: Writing – review & editing
                Role: ConceptualizationRole: Funding acquisitionRole: InvestigationRole: MethodologyRole: Project administrationRole: ResourcesRole: Writing – review & editing
                Role: Funding acquisitionRole: InvestigationRole: MethodologyRole: Project administrationRole: ResourcesRole: Writing – review & editing
                Role: Funding acquisitionRole: InvestigationRole: MethodologyRole: Project administrationRole: ResourcesRole: Writing – review & editing
                Role: ConceptualizationRole: Funding acquisitionRole: InvestigationRole: MethodologyRole: Project administrationRole: ResourcesRole: SupervisionRole: Writing – review & editing
                Role: Academic Editor
                Journal
                PLoS Med
                PLoS Med
                plos
                PLOS Medicine
                Public Library of Science (San Francisco, CA USA )
                1549-1277
                1549-1676
                27 April 2023
                April 2023
                : 20
                : 4
                : e1004221
                Affiliations
                [1 ] MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge, United Kingdom
                [2 ] Alliance for Research in Exercise, Nutrition and Activity, UniSA Clinical and Health Sciences, University of South Australia, Adelaide, Australia
                [3 ] Nutritional Biomarker Laboratory, National Institute for Health Research Biomedical Research Centre, School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom
                [4 ] Nutrition & Health Innovation Research Institute, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia
                [5 ] Medical School, University of Western Australia, Perth, Australia
                [6 ] Navarra Public Health Institute, Pamplona, Spain
                [7 ] CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain
                [8 ] Navarra Institute for Health Research (IdiSNA), Pamplona, Spain
                [9 ] Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany
                [10 ] German Center for Diabetes Research (DZD), Munich-Neuherberg, Germany
                [11 ] Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany
                [12 ] Key Laboratory of Growth Regulation and Translation Research of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, China
                [13 ] Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy
                [14 ] Unit of Nutrition and Cancer, Catalan Institute of Oncology—ICO, L’Hospitalet de Llobregat, Barcelona, Spain
                [15 ] Nutrition and Cancer Group, Bellvitge Biomedical Research Institute—IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain
                [16 ] Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain
                [17 ] Research Group on Demography and Health, National Faculty of Public Health, University of Antioquia, Medellín, Colombia
                [18 ] Deep Digital Phenotyping Research Unit, Department of Precision Health, Luxembourg Insitute of Health, Strassen, Luxembourg
                [19 ] Center of Epidemiology and Population Health UMR 1018, Inserm, Paris South—Paris Saclay University, Gustave Roussy Institute, Villejuif, France
                [20 ] Department of Clinical Sciences, Lund University, Malmö, Sweden
                [21 ] Vitas AS, Oslo, Norway
                [22 ] Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
                [23 ] Institute of Nutrition and Food Technology (INYTA) ‘José Mataix’, Biomedical Research Centre, University of Granada, Granada, Spain
                [24 ] Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain
                [25 ] Department of Nutrition and Food Science, University of Granada, Granada, Spain
                [26 ] Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network—ISPRO, Florence, Italy
                [27 ] Department of Mental, Physical Health and Preventive Medicine, University “L. Vanvitelli”, Naples, Italy
                [28 ] Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
                [29 ] Department of Public Health and Clinical Medicine, Family Medicine, Umeå University, Umeå, Sweden
                [30 ] Unit of Cancer Epidemiology, Città della Salute e della Scienza University-Hospital, Turin, Italy
                [31 ] Danish Cancer Society Research Center, Copenhagen, Denmark
                [32 ] Department of Public Health, University of Copenhagen, Copenhagen, Denmark
                [33 ] Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
                [34 ] BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
                [35 ] NIHR Blood and Transplant Research Unit in Donor Health and Genomics, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
                [36 ] British Heart Foundation Cambridge Centre of Excellence, Division of Cardiovascular Medicine, Addenbrooke’s Hospital, Cambridge, United Kingdom
                [37 ] Department of Human Genetics, Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom
                [38 ] Health Data Research UK Cambridge, University of Cambridge, Cambridge, United Kingdom
                [39 ] School of Public Health, Imperial College London, London, United Kingdom
                Carolina Population Center, UNITED STATES
                Author notes

                I have read the journal’s policy and the authors of this manuscript have the following competing interests: Authors declare support from the UK Medical Research Council, British Heart Foundation, Wellcome Trust, European Research Council, Swedish Research Council and National Institute for Health Research Cambridge Biomedical Research Centre for the submitted work. FI is a member of PLOS Medicine’s editorial board. PWF reports support for the submitted work from Novo Nordisk Foundation and consulting for Zoe Limited. JD reports grants, personal fees and non-financial support from Merck Sharp & Dohme (MSD), grants, personal fees and non-financial support from Novartis, grants from Pfizer and grants from AstraZeneca outside the submitted work. JD sits on the International Cardiovascular and Metabolic Advisory Board for Novartis (since 2010); the Steering Committee of UK Biobank (since 2011); the MRC International Advisory Group (ING) member, London (since 2013); the MRC High Throughput Science ‘Omics Panel Member, London (since 2013); the Scientific Advisory Committee for Sanofi (since 2013); the International Cardiovascular and Metabolism Research and Development Portfolio Committee for Novartis; and the Astra Zeneca Genomics Advisory Board (2018). ASB reports institutional grants outside the submitted work from AstraZeneca, Bayer, Biogen, BioMarin, Bioverativ, Novartis and Sanofi. Authors otherwise report no financial relationships with any organisations that might have an interest in the submitted work in the previous three years and no other relationships or activities that could appear to have influenced the submitted work.”

                Author information
                https://orcid.org/0000-0003-2641-2313
                https://orcid.org/0000-0002-6841-8396
                https://orcid.org/0000-0002-3866-2603
                https://orcid.org/0000-0003-2375-1440
                https://orcid.org/0000-0001-9998-051X
                https://orcid.org/0000-0001-6184-7764
                https://orcid.org/0000-0001-9242-6364
                https://orcid.org/0000-0002-0830-5277
                https://orcid.org/0000-0001-6560-4890
                https://orcid.org/0000-0003-4472-1179
                https://orcid.org/0000-0002-6700-0780
                https://orcid.org/0000-0001-5033-5966
                https://orcid.org/0000-0002-0520-7604
                https://orcid.org/0000-0003-3478-4758
                https://orcid.org/0000-0002-6509-6555
                https://orcid.org/0000-0002-0428-2426
                https://orcid.org/0000-0002-5652-8459
                https://orcid.org/0000-0002-4102-6835
                https://orcid.org/0000-0002-8008-5096
                https://orcid.org/0000-0003-4385-2097
                https://orcid.org/0000-0002-0284-8959
                https://orcid.org/0000-0002-4605-435X
                https://orcid.org/0000-0002-6915-9015
                https://orcid.org/0000-0001-6795-6080
                https://orcid.org/0000-0003-1422-2993
                https://orcid.org/0000-0002-5041-248X
                Article
                PMEDICINE-D-22-02857
                10.1371/journal.pmed.1004221
                10138823
                37104291
                c0d77559-8ffa-4667-b6f1-1ec779c6d6ae
                © 2023 Sobiecki et al

                This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                : 2 September 2022
                : 15 March 2023
                Page count
                Figures: 2, Tables: 2, Pages: 23
                Funding
                Funded by: National Health and Medical Research Council
                Award ID: #APP1050949
                Award Recipient :
                Funded by: funder-id http://dx.doi.org/10.13039/501100004965, Sixth Framework Programme;
                Award ID: LSHM_CT_2006_037197
                Award Recipient :
                Funded by: MRC Cambridge Initiative
                Award ID: RG71466
                Award Recipient :
                Funded by: MRC Cambridge Initiative
                Award ID: SJAH/004
                Award Recipient :
                Funded by: funder-id http://dx.doi.org/10.13039/501100000265, Medical Research Council;
                Award ID: MR/L003120/1
                Award Recipient :
                Funded by: funder-id http://dx.doi.org/10.13039/501100000274, British Heart Foundation;
                Award ID: RG/13/13/30194
                Award Recipient :
                Funded by: funder-id http://dx.doi.org/10.13039/501100000274, British Heart Foundation;
                Award ID: RG/18/13/33946
                Award Recipient :
                Funded by: funder-id http://dx.doi.org/10.13039/100011102, Seventh Framework Programme;
                Award ID: HEALTH-F2-2012-279233
                Award Recipient :
                Funded by: European Research Council
                Award ID: 268834
                Award Recipient :
                Funded by: funder-id http://dx.doi.org/10.13039/501100018956, NIHR Cambridge Biomedical Research Centre;
                Award ID: IS-BRC-1215-20014
                Award Recipient :
                Funded by: Health Data Research UK
                Award Recipient :
                Funded by: funder-id http://dx.doi.org/10.13039/100008700, Centre International de Recherche sur le Cancer;
                Funded by: funder-id http://dx.doi.org/10.13039/501100014534, School of Public Health, Imperial College London;
                Funded by: funder-id http://dx.doi.org/10.13039/501100013342, NIHR Imperial Biomedical Research Centre;
                Funded by: Danish Cancer Society
                Funded by: funder-id http://dx.doi.org/10.13039/501100004099, Ligue Contre le Cancer;
                Funded by: funder-id http://dx.doi.org/10.13039/501100008017, Institut Gustave-Roussy;
                Funded by: Mutuelle Générale de l’Education Nationale
                Funded by: Institut National de la Santé et de la Recherche Médicale (INSERM)
                Funded by: German Cancer Aid
                Funded by: German Cancer Research Center
                Funded by: German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE)
                Funded by: funder-id http://dx.doi.org/10.13039/501100002347, Bundesministerium für Bildung und Forschung;
                Funded by: funder-id http://dx.doi.org/10.13039/501100006695, Associazione Iblea per la Ricerca Epidemiologica;
                Funded by: funder-id http://dx.doi.org/10.13039/501100005010, Associazione Italiana per la Ricerca sul Cancro;
                Funded by: funder-id http://dx.doi.org/10.13039/100007388, Compagnia di San Paolo;
                Funded by: National Research Council and Sicilian Regional Government
                Funded by: funder-id http://dx.doi.org/10.13039/501100002999, Ministerie van Volksgezondheid, Welzijn en Sport;
                Funded by: Netherlands Cancer Registry
                Funded by: LK Research Funds
                Funded by: Dutch Prevention Funds
                Funded by: Zorg Onderzoek Nederland
                Funded by: funder-id http://dx.doi.org/10.13039/501100013514, Wereld Kanker Onderzoek Fonds;
                Funded by: Statistics Netherlands
                Funded by: funder-id http://dx.doi.org/10.13039/501100004587, Instituto de Salud Carlos III;
                Funded by: Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra
                Funded by: Catalan Institute of Oncology
                Funded by: Swedish Cancer Society
                Funded by: Swedish Research Council
                Funded by: Councils of Skåne and Västerbotten
                Funded by: funder-id http://dx.doi.org/10.13039/501100000289, Cancer Research UK;
                Award ID: 14136
                Award Recipient :
                Funded by: funder-id http://dx.doi.org/10.13039/501100000289, Cancer Research UK;
                Award ID: C8221/A29017
                Funded by: funder-id http://dx.doi.org/10.13039/501100000265, Medical Research Council;
                Award ID: 1000143
                Award Recipient :
                Funded by: funder-id http://dx.doi.org/10.13039/501100000265, Medical Research Council;
                Award ID: MR/M012190/1
                Funded by: funder-id http://dx.doi.org/10.13039/501100000265, Medical Research Council;
                Award ID: MC_UU_00006/1
                Award Recipient :
                Funded by: funder-id http://dx.doi.org/10.13039/501100000265, Medical Research Council;
                Award ID: MC_UU_00006/3
                Award Recipient :
                Funded by: Federal Ministry of Education and Research and the State of Brandenburg
                Award ID: DZD grant 82DZD03D03
                Award Recipient :
                Funded by: funder-id http://dx.doi.org/10.13039/100018928, Westlake University;
                Award ID: YSYY0209
                Award Recipient :
                Funded by: funder-id http://dx.doi.org/10.13039/100010665, H2020 Marie Skłodowska-Curie Actions;
                Award ID: 701708
                Award Recipient :
                Funded by: funder-id http://dx.doi.org/10.13039/501100004191, Novo Nordisk;
                Award Recipient :
                Funded by: Swedish Diabetes Association
                Award Recipient :
                Funded by: Swedish Heart-Lung Foundation
                Award Recipient :
                Funded by: European Research Council
                Award Recipient :
                Funded by: Imperial College Biomedical Research Centre
                Award Recipient :
                The MedLey trial was funded by a National Health and Medical Research Council Grant (#APP1050949 to KJM). The InterAct project was funded by the EU FP6 programme (grant number LSHM_CT_2006_037197 to NJW). Biomarker measurements for carotenoids were funded jointly by the InterAct project, the EPIC-CVD project, and the MRC Cambridge Initiative (RG71466 and SJAH/004 to NJW, NGF, JD, AB). EPIC-CVD has been supported by the UK Medical Research Council (MR/L003120/1 to ASB and JD), the British Heart Foundation (RG/13/13/30194 and RG/18/13/33946 to ASB and JD), the European Commission Framework Programme 7 (HEALTH-F2-2012-279233 to ASB and JD), the European Research Council (268834 to ASB and JD), and the National Institute for Health Research (NIHR; Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust, BRC-1215-20014 to ASB and JD). This work was also supported by Health Data Research UK (to ASB and JD), which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), and Wellcome. The coordination of EPIC is financially supported by the International Agency for Research on Cancer (IARC) and also by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London which has additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC). The national cohorts are supported by: Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany); Associazione Iblea Ricerca Epidemiologica (A.I.R.E. – ONLUS) Ragusa, Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di San Paolo, National Research Council and Sicilian Regional Government (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS) - Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology - ICO (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 to NJW; C8221/A29017), Medical Research Council (1000143 to NJW; MR/M012190/1) (United Kingdom). JGS was supported by the MRC PhD studentship. NJW, NGF, and FI acknowledge funding from the Medical Research Council Epidemiology Unit (MC_UU_00006/1, MC_UU_00006/3); and NJW, NGF and AK from the NIHR Cambridge Biomedical Research Centre (IS-BRC-1215-20014; NIHR203312). NGF and JD are NIHR Senior Investigators. JD holds a British Heart Foundation Professorship. MBS acknowledges funding from the Federal Ministry of Education and Research and the State of Brandenburg (DZD grant 82DZD03D03). JSZ has received funding from Westlake University (No YSYY0209) and European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 701708. PWF has received funding from Novo Nordisk, Swedish Diabetes Association, Swedish Heart-Lung Foundation, European Research Council. ER has received funding from Imperial College Biomedical Research Centre. The funders of the studies had no role in the study design, data collection, data analysis, data interpretation, or report preparation.
                Categories
                Research Article
                Biology and Life Sciences
                Biochemistry
                Biomarkers
                Biology and Life Sciences
                Nutrition
                Diet
                Medicine and Health Sciences
                Nutrition
                Diet
                Medicine and Health Sciences
                Endocrinology
                Endocrine Disorders
                Diabetes Mellitus
                Type 2 Diabetes
                Diet and Type 2 Diabetes
                Medicine and Health Sciences
                Medical Conditions
                Metabolic Disorders
                Diabetes Mellitus
                Type 2 Diabetes
                Diet and Type 2 Diabetes
                Medicine and Health Sciences
                Endocrinology
                Endocrine Disorders
                Diabetes Mellitus
                Type 2 Diabetes
                Medicine and Health Sciences
                Medical Conditions
                Metabolic Disorders
                Diabetes Mellitus
                Type 2 Diabetes
                Biology and Life Sciences
                Biochemistry
                Lipids
                Fatty Acids
                Physical Sciences
                Materials Science
                Materials
                Pigments
                Organic Pigments
                Carotenoids
                Medicine and Health Sciences
                Clinical Medicine
                Clinical Trials
                Randomized Controlled Trials
                Medicine and Health Sciences
                Pharmacology
                Drug Research and Development
                Clinical Trials
                Randomized Controlled Trials
                Research and Analysis Methods
                Clinical Trials
                Randomized Controlled Trials
                Medicine and Health Sciences
                Epidemiology
                Custom metadata
                Data from the MedLey trial contains sensitive participant information. For data access, please contact the University of South Australia Human Research Ethics Committee at humanethics@ 123456unisa.edu.au or researchintegrity@ 123456unisa.edu.au . EPIC-InterAct Study data cannot be deposited publicly as these collaborative data originate from multiple research institutions across eight European countries with different legal frameworks. The authors confirm that researchers seeking the analysis dataset for this work can submit a data request to the EPIC-InterAct study central contact point by emailing interact@ 123456mrc-epid.cam.ac.uk .

                Medicine
                Medicine

                Comments

                Comment on this article